Oxytocin vs Tadalafil Peptide
A side-by-side research comparison of Oxytocin and Tadalafil Peptide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Oxytocin | Tadalafil Peptide |
|---|---|---|
| Full name | Oxytocin (OXT) | Tadalafil-Peptide Conjugate (Experimental) |
| Category | Sexual Health | Sexual Health |
| Status | FDA Approved | Research compound |
| Mechanism | Binds OXTR in social cognition brain regions (amygdala, nucleus accumbens) and reproductive organs. Modulates serotonin and dopamine in reward circuits. | CPP moiety facilitates targeted PDE5 inhibitor delivery to penile smooth muscle. Local PDE5 inhibition increases cGMP for NO-mediated vasodilation with reduced systemic exposure. |
| Molecular weight | 1,007 Da | ~2,500 Da (conjugate) |
| Half-life | 3-5 min (IV) / 20-30 min (intranasal) | 8-12 hours |
| Bioavailability | Low (oral), Moderate (intranasal ~2-5%) | Targeted (topical/local) |
| Typical dose | 20-40 IU intranasal | 1-5 mg equivalent |
| Frequency | As needed or daily | As needed |
| Route | Intranasal or IV (obstetric) | Topical or local injection |
Oxytocin reported benefits
- Enhanced social bonding
- Improved intimacy
- Anxiolytic effects
- Pain modulation
- Post-orgasmic well-being
Tadalafil Peptide reported benefits
- Targeted PDE5 inhibition
- Reduced systemic side effects
- Potentially faster onset
- Lower dose requirement
Related comparisons
Research and educational reference only. Not medical advice.